Strategic Acquisition GenDx recently integrated with CareDx Lab Products, signaling a strategic consolidation of transplant diagnostics capabilities. This presents an opportunity to align product portfolios, cross-sell reagents, software, and HLA typing solutions to a broader customer base of transplant centers and labs.

NGS and qPCR Expansion There is active development of NGS-based solutions and a suite of qPCR assays targeting individual HLA markers. This indicates potential for upsell of next-generation sequencing workflows, assay kits, and related software for high-resolution typing and monitoring to current and new labs seeking comprehensive HLA solutions.

Training & Education GenDx is launching hands-on HLA typing training and education initiatives. This creates a channel to offer training services, certification programs, and premium support packages to labs expanding their capabilities, as well as to partner distributors seeking to upskill their customer base.

Collaborative CDx Potential Partnerships with Treos Bio for companion diagnostic work and PolyPEPI1018 development point to opportunities in oncology immunotherapy workflows. Sales opportunities exist for co-developed diagnostics, validation services, and integrated HLA-typing solutions within cancer immunotherapy programs.

Global Reach & Partnerships With 40 distributors and global operations, GenDx presents a channel-rich environment for expanding regional deployments, service contracts, and installed-base maintenance. A targeted partner and distributor enablement program could accelerate adoption of new qPCR/NGS assays and chimerism monitoring tools across markets.